– Appointment of Industry Leader Brings Broad
Strategic and Commercial Experience to Board –
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi
therapeutics company, announced today the election of Michael W.
Bonney to its Board of Directors. Mr. Bonney has served as Chief
Executive Officer of Cubist Pharmaceuticals and as a member of its
Board of Directors since June 2003. His experience prior to that
includes leadership positions in successful biotech and
pharmaceutical companies including Biogen Idec and Zeneca
Pharmaceuticals (now AstraZeneca).
“Mike is a recognized leader in the development and growth of
successful, commercial-stage biopharmaceutical companies. This
expertise will be very valuable to our Board, as we continue to
build Alnylam as a leading biotechnology company, ultimately
commercializing products from our pipeline of RNAi therapeutics,”
said John Maraganore, Ph.D., Chief Executive Officer of Alnylam.
“Given our robust clinical progress and our planned transition to a
commercial company in the coming years, Mike’s addition to our
Board comes at an opportune time as we advance RNAi therapeutics to
patients.”
“I am excited to join the Board of Alnylam, a highly innovative
biotechnology company, and a pioneer in advancing an entirely new
class of high-impact medicines with RNAi therapeutics. The progress
Alnylam has made in its clinical efforts has yielded very
encouraging results,” said Mike Bonney. “I look forward to working
with the management team and Board to contribute to the company’s
value creation strategy and execution.”
Michael W. Bonney has served as the Chief Executive Officer of
Cubist Pharmaceuticals and as a member of its Board of Directors
since June 2003. He is retiring from his CEO position and
transitioning to non-executive Chair of the Board effective
December 31, 2014. From January 2002 to June 2003, he served as
Cubist’s President and Chief Operating Officer. From 1995 to 2001,
Mike held various positions of increasing responsibility at Biogen,
including Vice President, Sales and Marketing from 1999 to 2001.
While at Biogen, he built the commercial infrastructure for the
launch of Avonex. Prior to that, Mike held various positions of
increasing responsibility in sales, marketing and strategic
planning at Zeneca Pharmaceuticals, ending his 11-year career there
serving as National Business Director. Cubist won a Catalyst Award
in 2013 for its outstanding record of diversity on its board,
senior leadership team and staff, corporate contributions of
volunteers, and funding to support STEM outreach initiatives
advancing girls and women. Mike received the MASSBio Innovative
Leadership Award in 2010. Mike earned a B.A. in Economics from
Bates College where he now serves as Chairman of the Board of
Trustees. He is a Director of NPS Pharmaceuticals, a PhrMA Board
Member (and former Board Member of BIO’s Health Section Governing
Body), and a Trustee of the TEKLA funds, which include the H&Q
Healthcare Investors and H&Q Life Sciences Investors funds.
About RNAi
RNAi (RNA interference) is a revolution in biology, representing
a breakthrough in understanding how genes are turned on and off in
cells, and a completely new approach to drug discovery and
development. Its discovery has been heralded as "a major scientific
breakthrough that happens once every decade or so," and represents
one of the most promising and rapidly advancing frontiers in
biology and drug discovery today which was awarded the 2006 Nobel
Prize for Physiology or Medicine. RNAi is a natural process of gene
silencing that occurs in organisms ranging from plants to mammals.
By harnessing the natural biological process of RNAi occurring in
our cells, the creation of a major new class of medicines, known as
RNAi therapeutics, is on the horizon. Small interfering RNA
(siRNA), the molecules that mediate RNAi and comprise Alnylam's
RNAi therapeutic platform, target the cause of diseases by potently
silencing specific mRNAs, thereby preventing disease-causing
proteins from being made. RNAi therapeutics have the potential to
treat disease and help patients in a fundamentally new way.
About Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel
therapeutics based on RNA interference, or RNAi. The company is
leading the translation of RNAi as a new class of innovative
medicines. In late 2014, Alnylam launched its pipeline growth
strategy for RNAi therapeutics in three strategic therapeutic areas
(STArs): Genetic Medicines, Cardio-metabolic Disease, and Hepatic
Infectious Disease. Alnylam’s Genetic Medicine STAr investigational
pipeline includes: patisiran (ALN-TTR02) targeting transthyretin
(TTR) for the treatment of TTR-mediated amyloidosis (ATTR) in
patients with familial amyloidotic polyneuropathy (FAP); revusiran
(ALN-TTRsc) targeting TTR for the treatment of ATTR in patients
with TTR cardiac amyloidosis, including familial amyloidotic
cardiomyopathy (FAC); ALN-AT3 targeting antithrombin (AT) for the
treatment of hemophilia and rare bleeding disorders (RBD); ALN-CC5
targeting complement component C5 for the treatment of
complement-mediated diseases; ALN-AS1 targeting aminolevulinic acid
synthase-1 (ALAS-1) for the treatment of hepatic porphyrias
including acute intermittent porphyria (AIP); ALN-AAT targeting
alpha-1 antitrypsin (AAT) for the treatment of AAT
deficiency-associated liver disease; ALN-TMP targeting TMPRSS6 for
the treatment of beta-thalassemia and iron-overload disorders;
ALN-GO1 targeting glycolate oxidase (GO) for the treatment of
primary hyperoxaluria type 1 (PH1); and other programs yet to be
disclosed. Alnylam’s Cardio-metabolic Disease STAr investigational
pipeline includes: ALN-PCSsc targeting PCSK9 for the treatment of
hypercholesterolemia; ALN-ANG targeting angiopoietin-like 3
(ANGPTL3) for the treatment of mixed hyperlipidemia and
hypertriglyceridemia; ALN-AC3 targeting apolipoprotein C-3 (apoC3)
for the treatment of hypertriglyceridemia; ALN-AGT targeting
angiotensinogen (AGT) for the treatment of hypertensive disorders
of pregnancy (HDP), including preeclampsia; and other programs yet
to be disclosed. Alnylam’s Hepatic Infectious Disease STAr
investigational pipeline includes: ALN-HBV targeting the hepatitis
B virus (HBV) genome for the treatment of HBV infection; ALN-HDV
targeting the hepatitis delta virus (HDV) genome for the treatment
of HDV infection; ALN-PDL targeting programmed death ligand 1
(PD-L1) for the treatment of chronic liver infections; and other
programs yet to be disclosed. The company’s demonstrated commitment
to RNAi therapeutics has enabled it to form major alliances with
leading companies including Merck, Medtronic, Novartis, Biogen
Idec, Roche, Takeda, Kyowa Hakko Kirin, Cubist, GlaxoSmithKline,
Ascletis, Monsanto, and The Medicines Company. In early 2014,
Alnylam and Genzyme, a Sanofi company, formed a multi-product
geographic alliance on Alnylam's genetic medicine programs in the
rare disease field. Specifically, Alnylam will lead development and
commercialization of programs in North America and Europe, while
Genzyme will develop and commercialize products in the rest of
world. In addition, Alnylam and Genzyme will co-develop and
co-commercialize revusiran in North America and Europe. In March
2014, Alnylam acquired Sirna Therapeutics, a wholly owned
subsidiary of Merck. In addition, Alnylam holds an equity position
in Regulus Therapeutics Inc., a company focused on discovery,
development, and commercialization of microRNA therapeutics.
Alnylam scientists and collaborators have published their research
on RNAi therapeutics in over 200 peer-reviewed papers, including
many in the world’s top scientific journals such as Nature, Nature
Medicine, Nature Biotechnology, Cell, New England Journal of
Medicine, and The Lancet. Founded in 2002, Alnylam maintains
headquarters in Cambridge, Massachusetts. For more information,
please visit www.alnylam.com.
Alnylam Forward-Looking Statements
Various statements in this release concerning Alnylam’s future
expectations, plans and prospects, including without limitation,
Alnylam’s views with respect to the potential for RNAi
therapeutics, its expectations regarding its STAr pipeline growth
strategy, and its plans regarding commercialization of RNAi
therapeutics, constitute forward-looking statements for the
purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995. Actual results may differ materially
from those indicated by these forward-looking statements as a
result of various important factors, including, without limitation,
Alnylam’s ability to discover and develop novel drug candidates and
delivery approaches, successfully demonstrate the efficacy and
safety of its drug candidates, the pre-clinical and clinical
results for its product candidates, which may not support further
development of product candidates, actions of regulatory agencies,
which may affect the initiation, timing and progress of clinical
trials, obtaining, maintaining and protecting intellectual
property, Alnylam’s ability to enforce its patents against
infringers and defend its patent portfolio against challenges from
third parties, obtaining regulatory approval for products,
competition from others using technology similar to Alnylam’s and
others developing products for similar uses, Alnylam’s ability to
manage operating expenses, Alnylam’s ability to obtain additional
funding to support its business activities and establish and
maintain strategic business alliances and new business initiatives,
Alnylam’s dependence on third parties for development, manufacture,
marketing, sales and distribution of products, the outcome of
litigation, and unexpected expenditures, as well as those risks
more fully discussed in the “Risk Factors” filed with Alnylam's
most recent Quarterly Report on Form 10-Q filed with the Securities
and Exchange Commission (SEC) and in other filings that Alnylam
makes with the SEC. In addition, any forward-looking statements
represent Alnylam’s views only as of today and should not be relied
upon as representing its views as of any subsequent date. Alnylam
explicitly disclaims any obligation to update any forward-looking
statements.
Alnylam Pharmaceuticals, Inc.Cynthia Clayton,
617-551-8207Vice President, Investor Relations and Corporate
CommunicationsorMedia:SpectrumLiz Bryan, 202-955-6222 x2526
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2024 to May 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From May 2023 to May 2024